Q9985 — Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
Q9985 is a HCPCS Level II code for injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg. It belongs to the Temporary Codes section. It was terminated on December 31, 2017 and is not valid on new claims.
This code has been terminated
CMS terminated Q9985 on December 31, 2017. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q9985
- Long descriptor
- Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
- Short descriptor
- Inj hydroxyprogst capoat nos
- Added
- July 1, 2017
- Terminated
- December 31, 2017
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to Q9985
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q9985 is not quite right, the correct code is very often within a few positions of it.
- Q9977Compounded drug, not otherwise classifiedterminated
- Q9978Netupitant 300 mg and palonosetron 0.5 mgterminated
- Q9979Injection, alemtuzumab, 1 mgterminated
- Q9980Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mgterminated
- Q9981Rolapitant, oral, 1 mgterminated
- Q9982Flutemetamol f18, diagnostic, per study dose, up to 5 millicuries
- Q9983Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries
- Q9984Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mgterminated
- Q9986Injection, hydroxyprogesterone caproate, (makena), 10 mgterminated
- Q9987Pathogen(s) test for plateletsterminated
- Q9988Platelets, pheresis, pathogen-reduced, each unitterminated
- Q9989Ustekinumab, for intravenous injection, 1 mgterminated
- Q9991Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg
- Q9992Injection, buprenorphine extended-release (sublocade), greater than 100 mg
- Q9993Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mgterminated
- Q9994In-line cartridge containing digestive enzyme(s) for enteral feeding, eachterminated
Questions about Q9985
What is HCPCS code Q9985?
Q9985 is a HCPCS Level II code for injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg. It sits in the Temporary Codes section.
Does Medicare cover Q9985?
The CMS HCPCS file marks Q9985 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is Q9985 still valid?
No. Q9985 was terminated on December 31, 2017 and should not be used on new claims.